Research Specifications
- IUPAC Name:
- Tirzepatide (LY3298176)
- CAS Number:
- 2023788-19-2
- Molecular Weight:
- 4813.5 Da
- Side Chain:
- C20 fatty diacid (enables albumin binding, once-weekly dosing)
- Form:
- Lyophilized powder
- Purity:
- ≥98% (HPLC verified)
- Storage:
- −20°C long-term / 4°C up to 4 weeks reconstituted
- Price per mg:
- $9.50
GLP-2 T 15mg
Dual GLP-1/GIP receptor agonist. SURMOUNT-1 trial: 22.5% mean body weight reduction at 15mg — the first approved dual incretin.
−22.5%
Mean Weight Reduction
SURMOUNT-1, 15mg (NEJM 2022)
2 receptors
Simultaneous Targets
GLP-1 + GIP
4813 Da
Molecular Weight
NCBI PubChem
Receptor Targets
Dual Incretin Agonism: GLP-1 & GIP Receptors
Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide with a C20 fatty diacid side-chain that enables once-weekly dosing via albumin binding. It simultaneously activates GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin sensitivity) and GIP receptors (enhancing glucose-stimulated insulin secretion and promoting adipocyte lipolysis). This dual mechanism outperforms GLP-1 monotherapy in head-to-head trials. It lacks the glucagon receptor component of Retatrutide, making it a 'step 2' rather than 'step 3' in the receptor-targeting progression.
Research Highlights
SURMOUNT-1 Trial (NEJM 2022)
2,539 participants across 72 weeks. The 15mg dose group achieved 22.5% mean body weight reduction vs 2.4% placebo. 37% of participants achieved ≥25% weight loss. The trial also demonstrated significant improvements in waist circumference, blood pressure, lipids, and fasting glucose — a comprehensive cardiometabolic profile.
GIP Receptor Advantage Over Semaglutide
Direct comparison trial (SURPASS-2) showed Tirzepatide 15mg produced 5.5% greater weight loss than Semaglutide 1mg at 40 weeks. The additional GIP agonism drives adipocyte-level lipolysis and may improve insulin secretion more effectively in high-fat dietary contexts.
Body Composition
SURMOUNT body composition sub-analysis showed the majority of weight loss was from fat mass, with lean mass preserved at a higher percentage than caloric restriction alone — consistent with GIP's hypothesized role in adipose-specific energy mobilization.
Research FAQ
What is the difference between Tirzepatide and Semaglutide?
How does Tirzepatide compare to Retatrutide?
What is the 15mg × 4 vial pricing per mg?
What is the C20 fatty diacid modification on Tirzepatide?
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| Apollo (via ClavTides) | >98% HPLC | $569.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Related Products
GLP-2 T 15mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-2 T 30mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-2 T 60mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-2 T 15mg (4 pack)
$569.99